Please login to the form below

Not currently logged in
Email:
Password:

CRISPR Therapeutics

This page shows the latest CRISPR Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology. Japanese pharma company Takeda has signed a collaboration agreement with KSQ Therapeutics to develop and market novel immune-based cancer therapies using its ... technology. KSQ’s

Latest news

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    In late March, Vertex was boosted further when its main challenger in the field, Proteostatis Therapeutics, reported disappointing results for its rival triple therapy candidate. ... These include alpha-1 antitrypsin deficiency and focal segmental

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease ... Meanwhile, CRISPR isn’t the only gene-editing

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing

  • Deal Watch May 2016 Deal Watch May 2016

    New CRISPR tech deals. After investing $335m in research support for a JV with CRISPR Therapeutics to discover, develop and commercialize new therapeutics to cure blood disorders, blindness, and congenital heart ... Financial details were not disclosed.

  • Deal Watch December 2015 Deal Watch December 2015

    440. Pieris (US). Roche. Collaboration, licence. Bispecific Anticalin-based protein therapeutics platform to discover immuno-oncology targets. ... 350. CRISPR Therapeutics (CH). Bayer Lifescience. Joint venture. Combining gene editing technology and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Lundberg most recently served as chief scientific officer of CRISPR Therapeutics, where he lead the development of the company’s first clinical trial application. ... Prior to CRISPR, he worked as head of translational medicine at Alexion

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform. ... Becker said: “I am excited to join the CRISPR Therapeutics

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors. ... Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics